Kuboki, Y., Yaeger, R., Fakih, M., Strickler, J. H., Masuishi, T., Kim, E.-H., … Hong, D. S. (2022). 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. In Annals of Oncology (Vol. 33, pp. S1445–S1446). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.10.077

Kuboki, Y., R. Yaeger, M. Fakih, J. H. Strickler, T. Masuishi, E. J. -. H. Kim, C. M. Bestvina, et al. “45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort.” In Annals of Oncology, 33:S1445–46. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.10.077.

Kuboki Y, Yaeger R, Fakih M, Strickler JH, Masuishi T, Kim EJ-H, et al. 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. In: Annals of Oncology. Elsevier BV; 2022. p. S1445–6.

Kuboki, Y., et al. “45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1445–46. Crossref, doi:10.1016/j.annonc.2022.10.077.

Kuboki Y, Yaeger R, Fakih M, Strickler JH, Masuishi T, Kim EJ-H, Bestvina CM, Langer CJ, Krauss JC, Puri S, Cardona P, Chang EK, Tran Q, Hong DS. 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Annals of Oncology. Elsevier BV; 2022. p. S1445–S1446.